Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01629498
Previous Study | Return to List | Next Study

Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01629498
Recruitment Status : Recruiting
First Posted : June 27, 2012
Last Update Posted : December 30, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
This partially randomized phase I/II trial studies the side effects and best dose of image-guided, intensity-modulated photon or proton beam radiation therapy and to see how well they work in treating patients with stage II-IIIB non-small cell lung cancer. This trial is testing a new way of delivering radiation dose when only the tumor receives dose escalation while the surrounding normal structure is kept at standard level. Photon beam radiation therapy is a type of radiation therapy that uses x-rays or gamma rays that come from a special machine called a linear accelerator (linac). The radiation dose is delivered at the surface of the body and goes into the tumor and through the body. Proton beam radiation therapy is a type of radiation therapy that uses streams of protons (tiny particles with a positive charge) to kill tumor cells. Both methods are designed to give a higher than standard dose of treatment to the tumor and may reduce the amount of radiation damage to healthy tissue near a tumor.

Condition or disease Intervention/treatment Phase
Recurrent Lung Non-Small Cell Carcinoma Stage II Non-Small Cell Lung Cancer AJCC v7 Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7 Stage IIIB Lung Non-Small Cell Cancer AJCC v7 Radiation: Image Guided Radiation Therapy Radiation: Intensity-Modulated Radiation Therapy Other: Laboratory Biomarker Analysis Radiation: Photon Beam Radiation Therapy Radiation: Proton Beam Radiation Therapy Other: Questionnaire Administration Phase 1 Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To establish the maximum tolerated dose (MTD) of image-guided intensity-modulated photon (IMRT) and proton therapy (IMPT) both with simultaneous integrated boost (SIB) dose escalation to the SIBVi (internal SIB volume; defined as the gross tumor volume with consideration of respiratory motion plus setup uncertainty margin) for patients with stage II/IIIB non-small cell lung cancer (NSCLC) receiving concurrent standard chemotherapy and proton irradiation. (Phase I) II. Assess and compare survival free of grade III treatment related toxicity and local progression-free survival from day 1 of concurrent chemoradiation for stage II-IIIB NSCLC patients treated with image-guided robustly-optimized IMPT versus (vs.) IMRT, both delivered with simultaneous integrated boost (SIB). (Phase II)

SECONDARY OBJECTIVES:

I. Determine treatment-related acute and late toxicity. II. Correlate changes in standardized uptake values (SUV) on positron emission tomography (PET) and study endpoints (toxicity, tumor response, local control).

III. Correlate changes in peripheral blood biomarkers (genes, micro-ribonucleic acid [RNA], proteins) and the study endpoints.

IV. Estimate progression-free and overall survival. V. Document and compare symptom burden before starting chemoradiation, weekly during treatment, bi-weekly from end of treatment until first follow up, and at each follow-up visit thereafter by using the MD Anderson Symptom Inventory - Plus (MDASI-Plus) and European Quality of Life Instrument-5 dimensions (EQ-5D).

VI. Perform cost effectiveness between IMPT and IMRT both with SIB treatment. VII. Correlate imaged response, clinical response, blood biomarkers and symptom burdens to dose distribution patterns.

OUTLINE: This is a phase I, dose-escalation study followed by a randomized phase II study.

PHASE I: Patients undergo image-guided IMRT with SIB or IMPT with SIB once daily (QD) 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.

PHASE II: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients undergo image-guided IMRT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.

ARM II: Patients undergo image-guided IMPT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 4-8 weeks, every 3-4 months for 3 years, every 6 months for 2 years, and then annually thereafter.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Trial of Image-Guided, Intensity-Modulated Photon (IMRT) or Scanning Beam Proton Therapy (IMPT) Both With Simultaneous Integrated Boost (SIB) Dose Escalation to the Gross Tumor Volume (GTV) With Concurrent Chemotherapy for Stage II/III Non-Small Cell Lung Cancer (NSCLC)
Actual Study Start Date : September 17, 2012
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : September 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm I (image-guided IMRT)
Patients undergo image-guided IMRT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
Radiation: Image Guided Radiation Therapy
Undergo image-guided IMRT
Other Names:
  • IGRT
  • image-guided radiation therapy

Radiation: Intensity-Modulated Radiation Therapy
Undergo image-guided IMRT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • Intensity-Modulated Radiotherapy

Other: Laboratory Biomarker Analysis
Optional correlative studies

Radiation: Photon Beam Radiation Therapy
Undergo image-guided IMRT

Other: Questionnaire Administration
Ancillary studies

Experimental: Arm II (image-guided IMPT)
Patients undergo image-guided IMPT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
Radiation: Image Guided Radiation Therapy
Undergo image-guided IMPT
Other Names:
  • IGRT
  • image-guided radiation therapy

Radiation: Intensity-Modulated Radiation Therapy
Undergo image-guided IMPT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • Intensity-Modulated Radiotherapy

Other: Laboratory Biomarker Analysis
Optional correlative studies

Radiation: Proton Beam Radiation Therapy
Undergo image-guided IMPT
Other Names:
  • PBRT
  • Proton Radiation Therapy

Other: Questionnaire Administration
Ancillary studies




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) for intensity-modulated photon therapy (IMRT) (Phase I) [ Time Frame: 90 days ]
    Will be defined as the highest simultaneous integrated boost volume (SIBV) dose that has posterior probability of dose-limiting toxicity (DLT) =< 30%. DLT are defined as Common Terminology Criteria for Adverse Events (CTCAE) 4.0 grade 3+ acute radiation toxicity, including esophagitis, pneumonitis, and skin reaction that are definitely, or probably related to radiation treatment. Toxicities will be tabulated by dose, severity, and relationship to radiation therapy.

  2. MTD for intensity-modulated proton therapy (IMPT) (Phase I) [ Time Frame: 90 days ]
    Will be defined as the highest SIBV dose that has posterior probability of DLT =< 30%. DLT are defined as CTCAE 4.0 grade 3+ acute radiation toxicity, including esophagitis, pneumonitis, and skin reaction that are definitely, or probably related to radiation treatment. Toxicities will be tabulated by dose, severity, and relationship to radiation therapy.

  3. Survival free of grade >= 3 toxicity (with a target of at least 75%) (Phase II) [ Time Frame: 6 months ]
  4. Local progression-free survival (75% at 6 months) d (Phase II) [ Time Frame: 6 months ]
    Will be defined as tumor recurrence or progression inside or at the boundary of the volume defined by the 60 Gy (relative biological effectiveness) isodose line. A Bayesian method will be applied.


Secondary Outcome Measures :
  1. Time to local failure (Phase II) [ Time Frame: Up to 5 years ]
    The product-limit estimator of Kaplan and Meier will be used.

  2. Progression-free survival (Phase II) [ Time Frame: Up to 5 years ]
    The product-limit estimator of Kaplan and Meier will be used.

  3. Overall survival (Phase II) [ Time Frame: Up to 5 years ]
    The product-limit estimator of Kaplan and Meier will be used.

  4. Posterior probability that the DLT rate 90 days from day 1 of radiation therapy is more than 30% (Phase II) [ Time Frame: 90 days ]
    A 90% credible interval will be reported for this rate. Toxicities will be tabulated by severity and relationship to radiation therapy.

  5. Changes in selected biomarkers (Phase II) [ Time Frame: Baseline to up to 5 years ]
    Correlate changes in peripheral blood biomarkers (genes, ctDNA, microRNA, exosomes, proteins) and the study endpoints. Cox proportional hazards regression will be used to estimate the relationship between changes in selected biomarkers and time to local failure, progression-free survival, and overall survival.

  6. Change in symptom burden using European Quality of Life Five Dimension [EQ-5D]) (Phase II) Survey [ Time Frame: Up to 10 minutes ]
    Descriptive statistics and box plots will be used and will be measured by participants answers to the survey.

  7. Change in symptom burden using MD Anderson Symptom Inventory [MDASI]-Plus Survey [ Time Frame: Up to 10 minutes ]
    Descriptive statistics and box plots will be used and will be measured by participants answers to the survey.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathologically proven diagnosis of unresected stage II-IIIB, or recurrent after surgical resection or stereotactic body radiation therapy (SBRT) non-small cell lung cancer
  • Suitability for concurrent chemoradiation therapy per treating physician's assessment
  • Karnofsky performance status (KPS) score >= 70
  • Weight loss < 15% in the 3 months before diagnosis
  • Prior receipt of induction chemotherapy followed by referral for concurrent chemoradiation is allowed
  • Adequate lung function indicated by forced expiratory volume at 1 second (FEV1) >= 1 L is required
  • The primary tumor and/or regional lymph nodes must be evaluable radiographically
  • The gross target volume (GTV) is suitable for motion management using 4 dimensional computed tomography (4D CT), internal target volume (ITV), or respiratory gating; in addition, the target coverage and normal tissue constraints must be met as specified in protocol accounting for the respiratory motion of anatomy as a whole (not just the tumor)
  • No prior radiation to the mediastinal structures
  • Hemoglobin >= 9.0 g/dL
  • Absolute neutrophil count (ANC) >= 1,500/mm^3
  • Platelet count >= 100,000/mm^3
  • Total bilirubin =< 1.5 times the upper limit of normal (ULN)
  • Alanine and aspartate transaminases (ALT and AST) =< 2.5 times the ULN (=< 5 x ULN for patients with liver involvement)
  • Creatinine =< 1.5 times ULN
  • Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of MD Anderson Cancer Center (MDACC)

Exclusion Criteria:

  • Prior radiotherapy to any anatomic regions that would result in overlap of radiation dose distribution to critical structures (esophagus, heart, spinal cord, brachial plexus)
  • T4 tumor with direct invasion of esophagus, spinal cord, major blood vessel, or heart
  • Pregnancy
  • Patients of childbearing potential must practice appropriate contraception
  • Patient refusal

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01629498


Contacts
Layout table for location contacts
Contact: Zhongxing Liao 713-563-2300 zliao@mdanderson.org

Locations
Layout table for location information
United States, Texas
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Zhongxing Liao    713-563-2300    zliao@mdanderson.org   
Principal Investigator: Zhongxing Liao         
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Zhongxing Liao M.D. Anderson Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT01629498    
Other Study ID Numbers: 2011-1058
NCI-2012-01224 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2011-1058 ( Other Identifier: M D Anderson Cancer Center )
P01CA021239 ( U.S. NIH Grant/Contract )
P30CA016672 ( U.S. NIH Grant/Contract )
U19CA021239 ( U.S. NIH Grant/Contract )
First Posted: June 27, 2012    Key Record Dates
Last Update Posted: December 30, 2019
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms